- Home
- JFU vs CMMB Comparison
JFU vs CMMB Comparison
Compare JFU & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- CMMB
- Stock Information
- Founded
- JFU 2006
- CMMB 2004
- Country
- JFU China
- CMMB Israel
- Employees
- JFU N/A
- CMMB N/A
- Industry
- JFU Finance: Consumer Services
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- JFU Finance
- CMMB Health Care
- Exchange
- JFU Nasdaq
- CMMB Nasdaq
- Market Cap
- JFU 17.1M
- CMMB 13.7M
- IPO Year
- JFU 2019
- CMMB N/A
- Fundamental
- Price
- JFU $4.92
- CMMB $3.13
- Analyst Decision
- JFU
- CMMB Strong Buy
- Analyst Count
- JFU 0
- CMMB 2
- Target Price
- JFU N/A
- CMMB $26.50
- AVG Volume (30 Days)
- JFU 148.8K
- CMMB 273.9K
- Earning Date
- JFU 01-01-0001
- CMMB 11-13-2025
- Dividend Yield
- JFU N/A
- CMMB N/A
- EPS Growth
- JFU 3110.57
- CMMB N/A
- EPS
- JFU 3.04
- CMMB N/A
- Revenue
- JFU $44,573,690.00
- CMMB N/A
- Revenue This Year
- JFU N/A
- CMMB N/A
- Revenue Next Year
- JFU N/A
- CMMB N/A
- P/E Ratio
- JFU $1.64
- CMMB N/A
- Revenue Growth
- JFU 8.19
- CMMB N/A
- 52 Week Low
- JFU $1.01
- CMMB $2.39
- 52 Week High
- JFU $5.88
- CMMB $9.84
- Technical
- Relative Strength Index (RSI)
- JFU 65.28
- CMMB 49.62
- Support Level
- JFU $4.70
- CMMB $2.72
- Resistance Level
- JFU $5.37
- CMMB $3.44
- Average True Range (ATR)
- JFU 0.79
- CMMB 0.28
- MACD
- JFU 0.03
- CMMB -0.06
- Stochastic Oscillator
- JFU 73.29
- CMMB 35.34
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.